The calcs are simple. 10M TAM shown from the diagnosis data during pre-acquisition commercial DD, US$400 net per script stated by Management with 3 year contacts, sensitise the penetration and annual refills all you like.
Does the product sell? Yes.
Is it clinically proven as best in class? Yes.
Is there sufficient and relatively inelastic demand? Yes.
Is pricing known? Yes.
I suppose we play two different games. One in for cents, one in for dollars. But only one of those is really investing.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.3¢ |
Change
-0.003(0.85%) |
Mkt cap ! $563.7M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 30.5¢ | 28.3¢ | $1.694M | 5.835M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 282808 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 517818 | 14 |
View Market Depth
| Last trade - 11.53am 17/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |